



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

## **AMORFIX PROVIDES CORPORATE UPDATE ON ALS THERAPEUTIC PROGRAM**

**TORONTO, Ontario – July 8, 2008** – Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced that its therapy program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is on schedule for completion of antibody infusion studies this fall.

Amorfix recently hosted a meeting of its Scientific Advisory Board and research collaboration partner Biogen Idec (NASDAQ: BIIB) to review progress and data from this program. All parties were supportive of the program and approved the plan for the final ALS animal treatment study under the research collaboration. This study of antibody injection into ALS mice is expected to be completed in September with data and final analysis of results in the fourth quarter of calendar 2008.

"Our ALS program is on track for results of our antibody approach to treatment of this devastating disease later this year. We are currently testing two candidate antibody therapies at low and high dose regimes to compare their potential efficacy," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix. "We continue to develop an ALS vaccine as an alternate approach."

Biogen Idec has an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize biotherapeutics directed against ALS. If Biogen Idec exercises its option, Amorfix will receive an upfront payment and potential milestone payments in excess of US\$25 million under the license agreement. Amorfix will also receive royalties on commercial product sales. If the option is exercised, Biogen Idec will be responsible for completing preclinical and clinical development, regulatory approvals, manufacturing and commercialization.

### **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current*

*beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---